Long-term results of tacrolimus in cyclosporine- and prednisone-dependent myasthenia gravis

Neurology. 2005 May 10;64(9):1641-3. doi: 10.1212/01.WNL.0000160392.32894.6D.

Abstract

Seventy-nine patients with cyclosporine- and prednisone-dependent myasthenia gravis (MG) after thymectomy received tacrolimus for a mean of 2.5 +/- 0.8 years. Prednisone was withdrawn in all but two patients. Anti-acetylcholine antibodies and MG score for disease severity decreased significantly and muscular strength increased by 39%. Complete stable remission was achieved in 5% of patients and pharmacologic remission in 87.3%. All patients resumed full activities of daily living.

Publication types

  • Clinical Trial

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Anti-Inflammatory Agents / administration & dosage
  • Anti-Inflammatory Agents / adverse effects
  • Ataxia / chemically induced
  • Autoantibodies / blood
  • Autoantibodies / drug effects
  • Cyclosporine / administration & dosage
  • Cyclosporine / adverse effects*
  • Dizziness / chemically induced
  • Female
  • Humans
  • Immunosuppressive Agents / administration & dosage
  • Immunosuppressive Agents / adverse effects
  • Male
  • Middle Aged
  • Muscle Weakness / drug therapy
  • Muscle Weakness / etiology
  • Myasthenia Gravis / drug therapy*
  • Myasthenia Gravis / immunology
  • Myasthenia Gravis / physiopathology
  • Prednisone / administration & dosage
  • Prednisone / adverse effects*
  • Prospective Studies
  • Receptors, Cholinergic / immunology
  • Remission Induction
  • Renal Insufficiency / chemically induced
  • Tacrolimus / administration & dosage*
  • Tacrolimus / adverse effects
  • Thymectomy / statistics & numerical data
  • Time
  • Treatment Outcome

Substances

  • Anti-Inflammatory Agents
  • Autoantibodies
  • Immunosuppressive Agents
  • Receptors, Cholinergic
  • Cyclosporine
  • Prednisone
  • Tacrolimus